Protein tyrosine phosphatase receptor type E (PTPRE) regulates the activation of wild-type KIT and KIT mutants differently

[1]  I. Alvarez-Twose,et al.  Systemic Mastocytosis: Following the Tyrosine Kinase Inhibition Roadmap , 2020, Frontiers in Pharmacology.

[2]  Hui Zhao,et al.  Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib , 2020, Cell & Bioscience.

[3]  R. Roskoski.  The role of small molecule Kit protein-tyrosine kinase inhibitors in the treatment of neoplastic disorders. , 2018, Pharmacological research.

[4]  S. Wöhrl,et al.  Mastocytosis: from a Molecular Point of View , 2017, Clinical Reviews in Allergy & Immunology.

[5]  J. Olsen,et al.  KITD816V Induces SRC-Mediated Tyrosine Phosphorylation of MITF and Altered Transcription Program in Melanoma , 2017, Molecular Cancer Research.

[6]  S. Haan,et al.  Insights into ligand stimulation effects on gastro-intestinal stromal tumors signalling. , 2017, Cellular signalling.

[7]  P. Hrelia,et al.  Personalized Medicine in Gastrointestinal Stromal Tumor (GIST): Clinical Implications of the Somatic and Germline DNA Analysis , 2015, International journal of molecular sciences.

[8]  L. Rönnstrand,et al.  PI3 kinase is indispensable for oncogenic transformation by the V560D mutant of c-Kit in a kinase-independent manner , 2015, Cellular and Molecular Life Sciences.

[9]  J. Olsen,et al.  The PI3-kinase isoform p110δ is essential for cell transformation induced by the D816V mutant of c-Kit in a lipid-kinase-independent manner , 2014, Oncogene.

[10]  S. Agarwal,et al.  Src-like-adaptor protein (SLAP) differentially regulates normal and oncogenic c-Kit signaling , 2014, Journal of Cell Science.

[11]  J. Blay,et al.  Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial , 2013, The Lancet.

[12]  Ling Huang,et al.  Expression of stem cell factor in gastrointestinal stromal tumors: Implications for proliferation and imatinib resistance , 2012, Oncology letters.

[13]  Johan Lennartsson,et al.  Stem cell factor receptor/c-Kit: from basic science to clinical implications. , 2012, Physiological reviews.

[14]  N. Aoki,et al.  Protein tyrosine phosphatase PTPepsilonM negatively regulates PDGF beta-receptor signaling induced by high glucose and PDGF in vascular smooth muscle cells. , 2010, American journal of physiology. Cell physiology.

[15]  L. Rönnstrand,et al.  The D816V Mutation of c-Kit Circumvents a Requirement for Src Family Kinases in c-Kit Signal Transduction* , 2009, Journal of Biological Chemistry.

[16]  S. Aga-Mizrachi,et al.  Cytosolic Protein Tyrosine Phosphatase-ε Is a Negative Regulator of Insulin Signaling in Skeletal Muscle , 2008 .

[17]  J. Lasota,et al.  Mutations in gastrointestinal stromal tumors – a population‐based study from Northern Norway , 2007, Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS).

[18]  E. Rock,et al.  Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma , 2007, Clinical Cancer Research.

[19]  L. Rönnstrand,et al.  Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism , 2006, British Journal of Cancer.

[20]  Adrian A Canutescu,et al.  Analysis of KIT Mutations in Sporadic and Familial Gastrointestinal Stromal Tumors: Therapeutic Implications through Protein Modeling , 2005, Clinical Cancer Research.

[21]  S. Tripp,et al.  Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. , 2005, Human pathology.

[22]  E. Liu,et al.  Correlation of KIT and platelet-derived growth factor receptor α mutations with gene activation and expression profiles in gastrointestinal stromal tumors , 2005, Oncogene.

[23]  M. Ladanyi,et al.  Association of KIT exon 9 mutations with nongastric primary site and aggressive behavior: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  Hoguen Kim,et al.  Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. , 2003, Cancer research.

[25]  L. Ashman,et al.  Src Family Kinases Are Involved in the Differential Signaling from Two Splice Forms of c-Kit* , 2003, The Journal of Biological Chemistry.

[26]  R. Pazdur,et al.  Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  D. Heitjan,et al.  Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[28]  K.,et al.  Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c‐kit mutation Asp‐816 to Val , 1998, British journal of haematology.

[29]  Y. Suzuki,et al.  Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[30]  C. Heldin,et al.  Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C. , 1993, The EMBO journal.